LUGPA President Dr. Richard Harris: 2020 challenges

"The AACU has been discussing the evolution of state policy to ensure that biomarker testing, including PSA screening, is covered by payers," writes Ron Lanton, Esq.

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.

“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its future," says Chad Ellimoottil, MD, MS.

The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

The bill, H.R. 2474, would tie the Medicare physician fee schedule to the Medicare Economic Index (MEI), something the AACU and the AMA have long supported